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Other names: ADPEAF; EPT; Epitempin-1; ETL1; 
IB1099; uc001kjc.1 
Location: 10q23.33 
Local order: Plus strand orientation, between C10orf4 
(protein isoform FRA10AC1-2) and TMEM20 
(Transmembrane protein 20). 
DNA/RNA 
Note: LGI1 gene spans a 40,274 bp region of 
chromosome 10 (95,507,632 - 95,547,906). 
NCBI assembly annotation: 
NC_000010.9; NT_030059.12. 
Alternate Celera assembly: 
AC_000053.1; NW_924884.1. 
LGI1 is considered a metastasis suppressor gene; it is 
also implicated in Autosomal Dominant Lateral 
Temporal Lobe Epilepsy (ADLTE). 
Description 
The LGI1 gene was isolated by positional cloning from 
a glioblastoma cell line (T98G) bearing a balanced 
translocation t(10;19)(q24;q13). 
LGI1 gene comprises 8 exons. Exon 1 contains the 
5’UTR (224 bp) and encodes the start methione. The 
size of exon 8 and the position of the stop codon are 
different in isoform 1 and 2. The 3’UTR consists of 
356 bp in isoform 1 and of 386 bp in isoform 2. 
A minimal promoter region is located immediately 
upstream of the TSS. Two Poly (A) sites are predict 
by SVM from UCSC Genome Browser at the following 
positions: chr10:95547796-95547828 and 
chr10:95547881-95547919. 
STS markers: IB1099; EST307318; RH51322; SHGC-
155057. 
Transcription 
Isoform 1 mRNA is composed of 2290 bases. 
Alternative splicing produces isoform 2 consisting of 




Note: The unprocessed precursor of LGI1 comprises 
557 Amino Acids with a Molecular weight of 63818 
Da (isoform 1, UniProtKB/Swiss-Prot). Three potential 
N-linked glycosilation sites have been identified at AA 
positions: 192, 277 and 422. 
Isoform 2 includes a sequence variation (AA: 280-291) 
and lacks the C-terminal AA stretch (292-557) yielding 
a protein length of 291 AA (Isoform ID: O95970-2). 
Isoform 1 is potentially secreted. 
 
Organization of LGI1 gene, depicting isoform 1 exons (1-8); exon size: (bp); red: translated region; blue: 5'UTR and 3'UTR. 
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Predicted domains of LGI1 protein (isoform 1): signal peptide (SP, AA: 1-34); N-terminal LRRNT (AA: 41-71); LRRs domains 1-3 (AA: 
90-113, 114-137 and 138-161); C-terminal LRRCT (AA: 173-222). The C-terminal half includes the EAR/EPTP repeats 1-7 (AA: 224-
267, 270-313, 316-364, 365-415, 418-462, 463-506, and 509-552). 
Description 
The N-terminal sequence of LGI1 precursor consists of 
a cleavable N-terminal signal peptide and of three 
leucine-rich repeats (LRRs) flanked by N-terminal and 
C-terminal cysteine-rich domains (LRRNT and 
LRRCT). The LRR domains are structurally similar to 
arcs and are generally involved in protein-protein 
interaction. 
The C-terminal portion of LGI1 contains 7 repeats, 
termed Epilepsy Associated Repeats (EAR) or 
Epitempin (EPTP). The repeats potentially fold as beta-
sheet and form a seven-bladed beta-propeller structure. 
Similar domains, identified in a number of proteins, 
probably represent protein interfaces. Isoform 2 lacks 
the six C-terminal EAR/EPTP domains. 
Expression 
LGI1 is highly expressed in neural tissue, particularly 
in specific brain regions comprising both neurons ad 
glial cells; strong expression is also reported in some 
areas of the prostate, kidney, sebaceous glands, islets of 
Langerhans, endometrium, ovary and testis. 
Expression is low or absent in the majority of glioma, 
glioblastoma, neuroblastoma, melanoma and breast 
cancer cell lines. The decrease of LGI1 expression 
correlates with the increasing grade of malignancy i  
astrocytic gliomas. 
DNA microarray data substantiate high expression in 
brain, spinal cord, DRG, and in pituitary gland. 
The expression profiles by SAGE and EST number 
support high expression in cerebellum and cerebrum, 
peripheral nerve, and also in B-lymphocytes, eye, lung, 
muscle, testis, and thymus; low or absent expression in 
neoplasia and tumors. 
Localisation 
Isoform 1 can be secreted, whereas a shorter isoform 
(which might correspond to isoform 2) is retained 
within the cell. Some mutants of LGI1 (isoform 1) 
linked to ADLTE, fail to be secreted and remain in the
endoplasmic reticulum and Golgi. 
Function 
LGI1 is involved in the control of cell proliferation, cell 
migration and neurogenesis. Like other neuronal LRR 
proteins LGI1 may modulate synaptic function. 
Re-expression in LGI1-null glioblastoma cells 
decreases cell proliferation through the inhibition of the 
ERK1/2 pathway and consequent down-regulation of 
matrix metalloproteinases. Increased expression in 
neuroblastoma cells reduces proliferation and triggers 
intrinsic apoptosis by inhibiting the PI3K/AKT 
pathway. 
LGI1 forms membrane complexes with Kv1.1 
potassium channels within the cell antagonizing the N-
type inactivation by the Kvbeta1 subunit. It has been 
recognized as a ligand of the trans-membrane protein 
receptor ADAM22, which also causes seizure when 
mutated. 
Homology 
It belongs to a family comprising four highly 
homologous members denoted LGI1, LGI2, LGI3, and 
LGI4. 
LRR repeats flanked by cysteine rich regions, are also
part of adhesive proteins and receptors of the LRR 
superfamily. With respect to this domain LGI1 is 
particularly related to the Drosophila protein slit, 
involved in growth-cone guidance and neuronal 
migration; and to the portion of the mammalian Trk 
receptors involved in neurotrophin binding. These 
proteins are crucial for the development of the nervous 
system. A comparable role for LGI1 is consistent with 
its involvement in epilepsy and tumors. 
The C-terminal seven-fold repeat shows the largest 
identity with the other members of the LGI protein 
family, and with a segment of the G protein coupled 
receptor MASS1/VLGR1, which carries mutations in a 
mouse model of audiogenic epilepsy. 
Mutations 
Note: The human LGI1 gene disclosed about 200 
Single Nucleotide Polimorphism (SNP), NCBI  
Assembly Reference Cluster Report: rs1111820 - 
rs3083468. 
Heterozygous point mutations are associated with 
ADLTE. 
Large-scale homozygous mutations are linked to the 
development of brain malignancy. 
Apparently the incidence of brain tumors is not 
increased in ADLTE. 
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Germinal 
Several loss of function mutations (missense/nonsense, 
splicing, small deletions and insertions) have been 
reported in ADLTE patients. 
Somatic 
Complete loss of LGI1 expression is associated with 
malignant brain tumors. Rearrangement or deletion of 
the region 10q23-q26, following the complete loss of 
one copy of chromosome 10, frequently occurs in high-
grade gliomas. Genetic abnormalities in this region, 
comprising tumor suppressor genes such as PTEN and 
DMBT next to the metastasis suppressor LGI1 gene, 
enhance the malignant progression. Even if 
rearrangements or mutations of LGI1 locus are absent 
in low-grade tumors LGI1 expression is often reduce, 
possibly due to epigenetic silencing. 
Implicated in 
Malignant brain tumors 
Epilepsy with auditory features (ADLTE) 
To be noted 
Note: Consultation of “The Cancer Genome Anatomy 
Project” (CGAP) for breakpoints of region 10q24 
associated with cancer yielded several balanced and 
unbalanced abnormalities, raising the possibility that 
interruption of LGI1 gene may be implicated in 
additional cancer pathologies. 
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